Fulcrum Biotech has developed a modular, GMP-compliant manufacturing system for scaling therapeutic gene editing treatments. Incubated through UNSW's medicine research commercialisation program, they are currently in manufacturing validation for two rare disease programmes in partnership with international biotech sponsors. The team includes bioprocess engineers and regulatory specialists based across Sydney and Melbourne.